New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
07:54 EDTONVOOrganovo announces first delivery of 3D liver tissue
Organovo Holdings announced that it has performed its first 3D Liver tissue delivery. The achievement marks the delivery of Organovo’s 3D Liver tissue to a laboratory outside of the company to a key opinion leader for experimentation, and marks the achievement of a milestone along the pathway to commercial launch of its 3D liver tissue product. Organovo achieved the milestone ahead of its April target date, the company said. Organovo Chief Technology Officer Dr. Sharon Presnell said, “In developing these tissues, we have gone through a careful set of research studies involving many individual tissues, and greatly increased our ability to produce them. By the end of January, we expect to have bioprinted nearly four hundred 3D Liver tissues during the month.” Organovo also introduced updated guidance on the timing of its product launch. Organovo had planned to launch its 3D Liver tissue product by the end of December, but now expects to commence the commercial launch and start generating revenue through a services model prior to December 2014. The company anticipates that preclinical toxicology testing services can command prices in the high tens of thousands of dollars per compound for standard screening for liver alone.
News For ONVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
16:22 EDTONVOOrganovo narrows FY16 net cash utilization view to $32M-$34M from $32M-$36M
Subscribe for More Information
16:22 EDTONVOOrganovo affirms long-range outlook from liver tissue product
Subscribe for More Information
16:20 EDTONVOOrganovo lowers FY16 revenue view to $700,000-$900,000 from $1.2M-$1.4M
Subscribe for More Information
16:19 EDTONVOOrganovo reports Q3 EPS (11c), consensus (11c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use